We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TIVICAY (ViiV Healthcare Pty Ltd)
Product name
TIVICAY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
166 working days (255)
Active ingredients
dolutegravir
Registration type
EOI
Indication
TIVICAY (film-coated tablet) is now indicated for the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in adults and children over 6 years of age (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Dual regimens).